Benjamin Oakes, PhD

Benjamin L. Oakes, PhD, is Co-founder, President, and Chief Executive Officer at Scribe Therapeutics, a molecular engineering company focused on creating best-in-class CRISPR-based therapies that permanently treat the underlying cause of disease through CRISPR by Design™. He has contributed to over 35 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. A previous Innovative Genomics Institute Entrepreneurial Fellow, Dr. Oakes has been named to the MIT Technology Review 35 Innovators Under 35, San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in Biopharma, Business Insider 30 Under 40 Transforming Healthcare, and the Biocom Life Sciences Catalyst Awards. He received a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics.